Objective To evaluate the efficacy of catgut implantation at acupoint for acute ulcerative colitis and its safety.Methods Reference to Medline, EMbase, Cochrane Library, CBM, CNKI, VIP and Articles database, two independent investigators extracted data according to the inclusion and exclusion criteria, evaluated quality of included literature quality with criteria of the Cochrane Collaboration of randomized controlled trials, Meta analyzed the result by RevMan 5.2 software.Results Eight documents and 626 cases of patients were included. The clinical efficacy of Catgut Implantation group[RR=1.13,95%CI(1.05,1.20)] was better than the control group. Eight documents did not report complete remission rate, in which one reported recurrence rate, and the difference between Catgut Implantation group and control group was not statistically significant[RR=1.50, 95%CI(0.27,8.34)]. In the included documents, four didn’t show significant adverse reactions, three did not mention safety or adverse reactions, and two reported adverse reactions. In Catgut Implantation group, one had rejection, one got infection, one had halo pin, while one had halo pin and some patients experienced nausea, impaired liver function in control group.Conclusion Catgut Implantation on acute ulcerative colitis is better in terms of improving clinical efficacy. However, as the sample size is too small and drug safety is not clear, high-quality randomized controlled trials is still needed for further validation.

Evidence-based guideline of the diagnosis and treatment in the nonalcoholic fatty liver disease was formulated by Chinese Medical Association of fatty liver disease and alcoholic liver disease in order to simplify medical decision making and to help physicians make good decisions about NAFLD,which was published in 2006.Compared with some international guidelines or recommendations,Chinese guideline is more wide and complete for diagnosis and therapy of NAFLD.Meanwhile,there is significant difference in evaluation and treatment between these guidelines.

OBJECTIVE:To study the effect of Shenfu injection(SFI)on the expression profile of myocardial miRNA in rats with chronic congestive heart failure (referring to heart failure). METHODS:40 rats were randomly divided into sham operation group (normal saline,ip),model group (normal saline,ip),valsartan group (positive control,10 mg/kg,ig) and SFI group (0.75 mL/kg,im),10 in each group. Except for sham operation group,another groups were reduced heart failure. After modeling, rats in other groups received related medicines,once a day. Affymetrix miRNA V4.0 chip technology was conducted to analyze the miRNA expression in myocardial tissue of rats with heart failure after administration for 28 d,and screen the miRNA on common differential expression in myocardial tissue of rats in each group. The miRNA associated with heart failure was analyzed by thresh-old of differential gene expression multiple value greater than or equal to 1.1. Gene Ontology (GO) analysis was used to analyze functional classification and biological signaling pathway of differentially expressed genes. RESULTS:There were totally 29 miR-Nas on common differential expression and 7 miRNAs associated with heart failure (rno-miR-30c-1-3p, rno-miR-125b-5p, rno-miR-133a-5p,rno-miR-199a-5p,rno-miR-221-3p,rno-miR-146a-5p and rno-miR-1-3p). SFI can significantly downregulate the expressions of rno-miR-125b-5p,rno-miR-133a-5p,rno-miR-221-3p,rno-miR-1-3p in myocardial tissue of rats (P<0.05 or P<0.01). Results of GO analysis showed,miRNAs on differential expression were mainly related to signal transduction,cytoplasm and nucleotide binding. CONCLUSIONS:SFI plays the role of anti-heart failure by participating in the downregulation of miRNAs associated with heart failure process and then affecting related signal pathways transduction after the combination of cyto-plasm and nucleotide.

Seven patients with nasopharyngeal carcinoma treated with ART were recruited . All patients were treated with SIB-IMRT regimen( named IMRT) . All patients had a second computed tomography scan after 10 fractions and a new plan based on this was initiated from fraction 11 ( ART1 ) . And a third CT scan after 21 fractions and a new plan based on this was initiated from fraction 22(ART2). When the treatment was finished,a fourth CT scan was made. Results revealed that the volumes of primary tumors and parotid glands regressed significantly after the teat-ment. The position of the parotid glands shifted medially an average of 4.5(1.6~9.2)mm during the plans. ART1 reduced mean dose to left parotid by 0. 42 Gy(1. 68%)(P=0.019) and right parotid by 0. 79 Gy (3.04%) (P=0. 013) over the IMRT alone. ART2 further reduced the mean left parotid dose by 0. 86 Gy or 3.5% ( P =0.001 ) and right parotid by 1 . 04 Gy or 4 . 13% ( P=0.035 ) .

Primary liver cancer is the third most common cause of death from cancer worldwide, and it is the second cause of cancer death in China. A variety of molecular markers and signaling pathways associated with hepatocarcinogenesis and tumor progression have been discovered in basic research in the recent decade. However, the 5 year survival of patients has not been remarkably improved, due in a large part to the late diagnosis and the limited treatment options. It seems that translational medicine should be accelerated to addres this problem. Translational medicine has been shown to bridge basic research and clinical practice in a B2B model: from bench to the bedside and bedside to the bench. It goes from the bench to bedside where theories emerging from preclinical experimentation are tested on patients, and from bedside to the bench, where information obtained from preliminary clinical sciences is used to refine the understanding of the biological principles. In liver cancer, diagnostic markers screening, development of molecular classification, and stratifying patients for targeted therapy are considered as exciting fields of translational medicine. The integration of basic and clinical sciences by translational medicine will improve not only the understanding of the underlying molecular mechanisms, but also the clinical outcomes in patients with primary liver cancer.

The incidence of hepatocellular carcinoma (HCC) has increased worldwide over the past two decades. Surgical resection and liver transplantation have been demonstrated as potentially curative treatment options, which could be considered in 30% -40% of HCC patients. Recent advancements of surgical treatment have focused not only on the surgical techpiques, but also the hepatic functional reserve evaluation, resectability assessment and the effects of biological characteristics of tumor on prognosis. There is no single variable to evaluate the hepatic functional reserve accurately. Combined Child-Pugh classification, ICGI5, portal vein pressure detection and remanent liver volume measurement are required prior to liver resection. The 5-year survival rate after liver resection for HCC is about 50%. The results are acceptable for some selected patients that underwent tumor resection with thrombectomy, including HCC with portal vein tumor thrombus or bile duct thrombosis. The choice of local resection or regular hepatectomy is still controversial although the former is commonly performed to treat HCC with cirrhosis, and the latter is applied to HCC patients without liver cirrhosis. The results of liver transplanta-tion for HCC are better than liver resection, and the Milan criteria is generally accepted. Any attempts to expand the selection criteria should be cautious because of organ shortage. Salvage transplantation for intrabepatic recurrence after liver resection may be a good choice in some resectable HCC. The recurrence and metastasis after surgical treatment are the main obstacles to achieve better results. Identification of predictive factors could be helpful to develop prevention strategies. Due to the importance of biological characteristics in tumor recurrence and metastasis, a molecular classification to predict prognosis of HCC patients will lead to a more personalized medicine. Targeting key molecules of biological pathways could optimize the therapeutic modality in HCC.

Cancer metastasis is considered as a complex process involving a series of sequential steps and a variety of molecalar signal transduction pathways.Tumor recurrence and metastasis are major obstacles for long-term survival of Liver cancer patients.Although the prognosis after recurrence and metastasis is dismal,the advancement of molecular researches of metastasis of liver cancer seems promising.In studies of origins of metastasis of liver cancer,the primary cancer cell and corresponding metastatic liver cancer cells share similar gene signature,which indicates that genes favoring metastasis progression are initiated in the primary tumors.The metastasis of liver cancer may be an early event in hepatic carcinogenesis and progression.Some molecular signatures have been developed to classify the metastatic potential of liver cancer.Furthermore,a variety of studies demonstrate that the tumor microenvironment instead of tumor cells plays a more important role in liver cancer metastasis.The pre-metastatic niche composed of non-tumoral cells may promote the cancer cell sedimentation and progression.The theory of cancer stem cell speculates that cancer stem cells were the real source of recurrent or metastatic tumors.Cancer stem cells will be one of the main targets of liver cancer treatment.The prevention and treatment of liver cancer recurrence or metastasis are quite difficult because liver cancer is resistant to traditional chemotherapy.Targeting the molecules involved in the metastasis of liver cancer WOuld be promising to cure those diseases.

Objective To understand the disease distribution and change rule of death causes by analyzing 8 670 dead cases in the First Affiliated Hospital of Southwest Medical University during Juhuary 1,2000 to December 31,2014.Methods The disease classification in 2000 and 2001 adopted the ICD-9 as the standard,which in other years adopted the ICD-10 as the standard.The medical records of dead hospitalized cases in our hospital during Juhuary 1,2000 to December 31,2014 were retrospectively analyzed by using the Excel 2007,SPSS17.0 software system.Results The sex ratio of male and female mortality was about 1.92 ∶ 1 in these 15 years,the sex ratio of heart disease death was 1.3 ∶ 1.In these 15 years,the number of hospitalized patients was increased rapidly,while the mortality rate was declined year by year.The age group of high mortality rate was 60 years old and over(4 281 cases),accounting for 49.38％.Especially heart disease patients over 60 years old accounted for 61.9％of total heart disease deaths.Followed by the age group of 45-59 years old,accounting for 20.30％.The top three causes of death were circulatory system diseases,respiratory diseases and malignant tumors.The top three causes of death in circulatory system diseases were coronary heart disease,cerebral hemorrhage and cerebral infarction.The top three causes of cardiovascular system were coronary heart disease,high blood pressure and congenital heart disease.The top three causes of respiratory disease were pneumonia,chronic obstructive pulmonary disease and respiratory failure.The top three death causes of malignant tumor were lung cancer,leukemia and liver cancer.According to the seasonal distribution,the number of deaths in winter was up to 2 362 cases,the constituent ratio was 27.24 ％.Hospitalization days,the number of hospitalization death≤1 d was up to 2 625 cases,the constituent ratio was 30.28％.Conclusion Analyzing the death causes,disease distribution and change trend of inpatients is conducive to the rational allocationof medical resources,promote the reform of hospital management programs and improve the level of clinical epidemiological research in this area.

Equitable,just and public allocation of health resources is an essential rule in organ transplantation.We reviewed the allocation principles of China and the United States of America and then proposed our strategy.First,establishing transplantation organ library is mainly depending on the medical organ transplantation society.Secondly,formulating the sorting and allocation rules of transplantation organ.Finally,upon the institutional review board,-ing surveillance and management institution to ensure equitable,just and public in allocation of health resources.

It is the prerequisite and foundation to set up the institutional ethics committee of organ transplantation that holds a proper structure for ethics committee to play a key role effectively.In terms of our reality and based on the successful practices and guidelines of international organizations of ethics committee,some suggestions and guidelines on reasonably standardizing the structure of ethics committee for organ transplantation in China are given to guarantee ethics committee to fulfill its target functions.